8 
Dr. BaltiJTore said that the concern raised in the Boston area is not a unique 
situation and that activities at the Federal level are still inportant. He 
uid that since there are differences in the science done at different insti- 
tuticns it is not suprising, and not relevant to the present discussion, that 
different IBCs in California operate differently. Dr. Baltimore en^asized 
his view that IBC prereview is a serious obstruction of science, v^iich results 
in scientific nonentun being lost. 
Dr. McKinney pointed out that the NIH could still choose to mandate guidelines 
even if the RAC recommends otherwise. He suggested that reference to CDC and 
USDA guidelines not be incorporated into the body of the text of the revised 
guidelines; rather they could be cited as references. 
Ms. King suggested that the RAC should structure the issues on which it wants 
public comment, such as treatment of prohibitions and the voluntary vs. 
nandatory nature of the guidelines. Dr. Tadbot pointed out that the RAC could 
follow Ms. King's suggestion and present issues for public comment. The 
adtemative would be for the RAC to accept the Working Group proposal, the 
Baltimore-Campbell proposal, or an amalgam of the two. Fallowing the meeting, 
NIH staff could then develop a new version of the Guidelines bas^ on the RAC 
proposal amd put this out for public comient. 
Dr. Harris then moved to accept the report of the Working Group so that dis- 
cussion could proceed to consider the report section by section. Dr. Mason 
seconded the motion. There followed discussion of the effect of such a 
motion. 
Dr. Ahmed praised the report of the Working Group. He favored publication for 
public comment of a series of different options. Dr. Mason expressed concern 
about eliminating all of the prohibitions. Dr. Saginor suggested that the 
RAC might first consider the Adelberg-Zinder minority proposal to abolish the 
Guidelines. Dr. McKinney said that he considered the Working Group's recon- 
mendations as too cursory. Dr. Gotte^ran responded that the Working Group had 
considered the issues in-depth at two meetings and had prepared a report on 
its evaluation of the risks associated with recombinant DNA research. The RAC 
could change or elaborate on the reccmmendations before seeking public comment. 
Dr. Zinder said that the recommendations of the Working Group were adopted 
unanimously for those concerning Part IV of the Guidelines. 
Dr. Baltimore, in the interests of providing a forvm for RAC discussion of the 
points of difference between the various proposals, moved a seven part motion 
as a substitute for Dr. Harris' motion: 
1. Acoept the first section of the Baltimo re-Campbell proposed, as follows; 
■Section I-A of the NIH Guidelines will be replaced with the 
following: 
( 199 ] 
